{
    "id": 6367,
    "name": "acral lentiginous melanoma",
    "source": "DOID",
    "definition": "A skin melanoma that is characterized by slow growth of a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin and occurs on occurs on non hair-bairing surfaces including hands and feet, subungual sites, and fingers or toes. [url:http\\://en.wikipedia.org/wiki/Acral_lentiginous_melanoma, url:http\\://en.wikipedia.org/wiki/Lentigo, url:http\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC1352575/]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:6367",
    "evidence": [
        {
            "id": 8417,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AT7519 in patient derived acral lentigineous melanoma cells co-harboring CDK4 amplification and loss of CDKN2A resulted in inhibition of cell proliferation in culture and suppression of tumor growth in the patient derived xenograft models (J Clin Oncol 34, 2016 (suppl; abstr 9512)).",
            "molecularProfile": {
                "id": 26316,
                "profileName": "CDK4 amp CDKN2A loss"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 6367,
                "name": "acral lentiginous melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6643,
                    "pubMedId": null,
                    "title": "Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy",
                    "url": "http://meetinglibrary.asco.org/content/167622-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8418,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acral lentiginous melanoma cells co-harboring CCND1 amplification and loss of CDKN2A demonstrated inhibition of cell proliferation when treated with AT7519 in culture (J Clin Oncol 34, 2016 (suppl; abstr 9512)).",
            "molecularProfile": {
                "id": 26317,
                "profileName": "CCND1 amp CDKN2A loss"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 6367,
                "name": "acral lentiginous melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6643,
                    "pubMedId": null,
                    "title": "Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy",
                    "url": "http://meetinglibrary.asco.org/content/167622-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15081,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Kadcyla (trastuzumab emtansine) treatment resulted in complete radiographic response that lasted over 28 months in a patient with acral melanoma harboring ERBB2 (HER2) amplification (26-fold) that was resistant to check-point inhibition (PMID: 30093446).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 6367,
                "name": "acral lentiginous melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12627,
                    "pubMedId": 30093446,
                    "title": "Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093446"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17736,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Toripalimab (JS001) demonstrated safety and preliminary efficacy, resulted in an objective response rate of 23.1% (3/13) and a disease control rate of 46.2% (6/13, 1 complete response, 2 partial response, 3 stable disease) in patients with acral melanoma (PMID: 30642373; NCT02836795).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 6367,
                "name": "acral lentiginous melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15756,
                    "pubMedId": 30642373,
                    "title": "Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30642373"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02731729",
            "title": "Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02879162",
            "title": "Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02978443",
            "title": "A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03817125",
            "title": "Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7801,
                    "therapyName": "Nivolumab + SER-401",
                    "synonyms": null
                },
                {
                    "id": 7815,
                    "therapyName": "Vancomycin",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04042506",
            "title": "SBRT as a Vaccination for Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04139902",
            "title": "PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7522,
                    "therapyName": "TSR-022 + TSR-042",
                    "synonyms": null
                },
                {
                    "id": 6320,
                    "therapyName": "TSR-042",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04244552",
            "title": "First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9330,
                    "therapyName": "ATRC-101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04250597",
            "title": "Study of GNX102 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9331,
                    "therapyName": "GNX102",
                    "synonyms": null
                }
            ]
        }
    ]
}